Until 2012, the basic pharmacological therapy for patients with symptomatic HF and a reduced left ventricular ejection fraction (LVEF) of ≤40% implied the combination of an angiotensin‐converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) and a beta‐blocker (BB).4 The gene discussed is ACE; the disease is hydrops fetalis.